Reata Pharmaceuticals Inc (NASDAQ:RETA) insider Keith Wayne Ward sold 4,750 shares of the stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $66.97, for a total value of $318,107.50. Following the transaction, the insider now owns 4,750 shares of the company’s stock, valued at $318,107.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Keith Wayne Ward also recently made the following trade(s):
- On Thursday, November 1st, Keith Wayne Ward sold 4,750 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $59.48, for a total value of $282,530.00.
- On Tuesday, October 23rd, Keith Wayne Ward sold 14,250 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $57.08, for a total value of $813,390.00.
NASDAQ:RETA opened at $65.78 on Friday. Reata Pharmaceuticals Inc has a fifty-two week low of $19.31 and a fifty-two week high of $99.50. The firm has a market cap of $1.87 billion, a P/E ratio of -33.06 and a beta of 3.40.
Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.79) by ($0.28). The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $9.50 million. As a group, equities analysts forecast that Reata Pharmaceuticals Inc will post -2.56 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its holdings in Reata Pharmaceuticals by 9.3% during the 3rd quarter. Rhumbline Advisers now owns 16,806 shares of the company’s stock valued at $1,374,000 after buying an additional 1,431 shares during the period. Lee Financial Co purchased a new stake in Reata Pharmaceuticals during the 3rd quarter valued at $128,000. Northern Trust Corp raised its holdings in Reata Pharmaceuticals by 1.4% during the 1st quarter. Northern Trust Corp now owns 129,984 shares of the company’s stock valued at $2,666,000 after buying an additional 1,735 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Reata Pharmaceuticals by 53.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 5,460 shares of the company’s stock worth $191,000 after purchasing an additional 1,897 shares during the period. Finally, American International Group Inc. increased its stake in Reata Pharmaceuticals by 19.7% in the third quarter. American International Group Inc. now owns 12,404 shares of the company’s stock worth $1,014,000 after purchasing an additional 2,044 shares during the period. Institutional investors own 40.73% of the company’s stock.
A number of research analysts have recently commented on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $100.00 target price on shares of Reata Pharmaceuticals in a research report on Monday, October 1st. Leerink Swann increased their price target on Reata Pharmaceuticals from $64.00 to $116.00 and gave the company an “outperform” rating in a report on Thursday, August 9th. LADENBURG THALM/SH SH restated a “buy” rating and set a $133.00 price target on shares of Reata Pharmaceuticals in a report on Wednesday, September 26th. BidaskClub lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, October 13th. Finally, Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 25th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $100.33.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/10/reata-pharmaceuticals-inc-reta-insider-keith-wayne-ward-sells-4750-shares.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Recommended Story: How can investors find ex-dividend dates?
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.